Quanterix Corporation, a Lexington, Mass.-based developer of ultrasensitive single molecule testing capabilities for life science research and diagnostics, secured $46m in Series D funding.
The round was led by new investors ARCH Overage Fund, Cormorant Asset Management and Trinitas Capital, with participation from existing investors ARCH Venture Partners, Bain Capital Ventures, Tufts University, Dr. David Walt and Hercules Capital.
The company intends to use the funds to develop desk-top instruments, expand the assay menu for protein and nucleic acid biomarkers, bolster the global channel to market and enable new, pivotal medical studies to be performed with its technology.
Established in 2007 by Kevin Hrusovsky, Executive Chairman and CEO, Quanterix develops the Simoa platform, a high definition diagnostics tools that uses single molecule measurements to access undetectable proteins, this bringing benefits to both research and clinical testing applications in key therapeutic areas including neurology, oncology, cardiology, inflammation and infectious disease.
FinSMEs
23/03/2016